key: cord-0771725-yr204pg2
authors: Chewcharat, Api; Chang, Yuan-Ting; Sise, Meghan E.; Bhattacharyya, Roby P.; Murray, Megan; Nigwekar, Sagar U.
title: Phase 3 Randomized Controlled Trials on Exclusion of Participants with Kidney Disease in COVID-19
date: 2020-10-21
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.10.010
sha: 58801b775dc128cce3b4f1bfc5510568dff8eee4
doc_id: 771725
cord_uid: yr204pg2

nan

and researchers whether and how findings from these trials can be applied to patients with kidney disease (AKI, CKD, or ESRD), we conducted a systematic review of registered trials and quantified the proportion of potential subjects with kidney disease who are excluded from enrollment. Variables predicting trials with exclusion criteria regarding kidney disease were also explored using multiple logistic regression.

A total of 248 trials were identified, of which 55 trials did not meet the inclusion criteria (13 trials were for unrelated topics, 4 trials were non-randomized single-arm interventions and 38 trials included less than 100 participants). Of the remaining 193 trials (representing 258,794 participants), 83 trials (43.0%) (representing 149,294 participants (57.7%)) excluded patients with kidney disease. Criteria to exclude patients with kidney disease included abnormal eGFR or renal replacement therapy (RRT) (n=57 trials), abnormal serum creatinine (n=6 trials), history of kidney stone (n=1 trial), history of nephrotic syndrome (n=1 trial), or renal impairment, not further specified (n=18 trials). The eGFR thresholds provided as exclusion cut-offs are summarized in Figure 1 .

The exclusion of patients with kidney disease occurred across the spectra of trials with varying sample sizes, funding sources, and outpatient/inpatient settings (Table 1) . Details on the exclusion criteria thresholds applied to each trial for each intervention were shown in Table   2 . The corresponding appropriate thresholds at which each intervention was contraindicated were represented in Supplementary Table S1. It appears that exclusion criteria regarding kidney disease are generally applied regardless of number of enrollments (100-499, 500-999, >1,000), participant settings (outpatient, inpatient, healthcare workers and not specified), locations (North America, South America, Africa, Asia/Australia, Europe and multiple locations) and funding sources (Academic/government, industry and not specified) as none of these factors were significantly different across various exclusion criteria regarding kidney disease as shown in Supplementary Table S2 . Moreover, none of these factors significantly predict whether or not trials have exclusion criteria regarding kidney disease. (Supplementary Table   S3 )

Almost all studies of humanized monoclonal antibodies such as tocilizumab or sarilumab, convalescent plasma and nonpharmacologic treatment such as hyperbaric oxygen therapy, where renal clearance is minimal or irrelevant, included participants with kidney disease. However, two trials (14%) with 410 participants (10%) among humanized monoclonal antibody trials excluded kidney impairment patients. On the contrary, most BCG vaccine trials did not exclude patients with kidney disease. Nonetheless, two trials (22%) with 1,380 participants (7%) excluded patients with CKD or dialysis patients. The rationale for excluding J o u r n a l P r e -p r o o f kidney impairment patients among BCG vaccination trials might be explained by the fact that renal impairment patients were considered as immunocompromised hosts. They might be at risk of disseminated or severe tuberculosis infection. However, according to the manufacture labeling, there is no contraindication or dose adjustment for this particular population.

By contrast, more than 50% of studies of small molecule antivirals such as remdesivir or favipiravir and antimalarials such as hydroxychloroquine or chloroquine excluded such participants. Regarding hydroxychloroquine/chloroquine, 20 trials (61%) with 41,229 participants (78%) excluded patients with renal impairment despite the fact that there is no requirement for dose adjustment for short-term use including treating COVID-19 patients. All remdesivir trials excluded participants with kidney disease (2 trials excluded participants with eGFR<50 ml/min/1.73m 2 and 1 trial excluded participants with eGFR<30 ml/min/1.73m 2 ), as discussed in Adamsick et al. 7 Although there is a contraindication among patients with eGFR<30 ml/min/1.73m 2 , some trials excluded participants at eGFR 50 ml/min/1.73m 2 .

Interestingly, some trials excluded patients with renal diagnoses not further specified kidney function. One trial excluded patients with a history of kidney stones as the experimental arm was vitamin C supplementation, which is associated with higher risk of kidney stones.

Another trial excluded patients with a history of nephrotic syndrome, because the proposed intervention was discontinuation of ACEI/ARB, which should not be discontinued among patients with nephrotic syndrome. Their rationales appear to be appropriate.

Most interventions including humanized monoclonal antibodies, hydroxychloroquine/chloroquine, lopinavir/ritonavir, convalescent plasma, vaccination, and hyperbaric oxygen are not contraindicated in renal impairment patients. However, renal dose for these interventions might be required. Many ongoing trials use strict criteria excluding patients with renal impairment without considering dose adjustment. This leads to loss of potential patients who might benefit from these interventions. The exclusion of patients with kidney disease, as highlighted in this report, will limit the generalizability of results of these trials to kidney disease population. Patients with severe kidney disease including those requiring RRT are the most vulnerable patient groups to COVID-19 that nephrology practitioners encounter.

The exclusion of these patients means that clinical decisions regarding their care will be less likely to be evidence-driven, exposing patients in some cases to excess risks and in some cases, depriving them of an effective intervention. Scientific rationale (lack of efficacy, safety concern, or other) should be provided for future trials that exclude patients with kidney disease.

Several studies exclude patients on the basis of weak measures of renal function. Some used serum creatinine rather than eGFR as the cutoff criteria, which might not be an accurate J o u r n a l P r e -p r o o f representation of underlying kidney disease. Moreover, 18 trials (9%) excluded patients on the basis of renal impairment not further specified which might lead to the exclusion of patients with mild kidney disease. We believe that eGFR should be utilized in order to be consistent with other trials, to more accurately reflect kidney function and to renally adjust medication doses.

Furthermore, future studies should record and clarify whether abnormal renal function is secondary to AKI, CKD, or AKI superimposed on CKD.

In conclusion, over 40% of COVID-19 trials excluded patients with kidney disease. Since patients with kidney disease are at high risk of COVID-19 exposure, infection and severe disease, and since COVID-19 itself leads to AKI, future trials should include patients with kidney disease (AKI, CKD, or ESRD) as suggested by the Kidney Health Initiative and the US Food and Drug Administration. 8, 9 eGFR rather than serum creatinine should be used to assess kidney function and to adjust doses of renally cleared interventions. Focusing on the efficacy and safety of various potential interventions for COVID-19 among kidney disease population is of critical importance.

SUN is supported by the American Heart Association (15FTF25980003) and by National Institute of Diabetes and Digestive and Kidney Diseases (1U01DK123818). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association or the National Institutes of Health.

MES has participated in scientific advisory boards for Gilead in the area of Viral Hepatitis. 

Coronavirus disease 2019 (COVID-19): A literature review

Acute kidney injury in patients hospitalized with COVID-19

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology

Update on the Burden of CKD

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International urology and nephrology

COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?

Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19

Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)

Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials